Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irina A Vasilevskaya

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Biochemical Pharmacology|July 5, 2005
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell linesIrina A Vasilevskaya, Peter J O'Dwyer
Molecular Pharmacology|April 26, 2008
Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatinIrina A Vasilevskaya, Muthu Selvakumaran, Peter J O'Dwyer
Cancer Research|June 18, 2003
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interactionIrina A Vasilevskaya, Tatiana V Rakitina, Peter J O'Dwyer
Cancer Research|December 26, 2003
Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signalingTatiana V Rakitina, Irina A Vasilevskaya, Peter J O'Dwyer
Biochemical Pharmacology|March 9, 2007
Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell linesTatiana V Rakitina, Irina A Vasilevskaya, Peter J O'Dwyer
Molecular Pharmacology|January 15, 2004
Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell linesIrina A Vasilevskaya, Tatiana V Rakitina, Peter J O'Dwyer
Molecular Cancer Research : MCR|May 25, 2016
JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to ChemotherapyIrina A Vasilevskaya, Muthu Selvakumaran, David Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2013
Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapyMuthu Selvakumaran, Ravi K Amaravadi, Irina A Vasilevskaya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2015
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging AgentsIrina A Vasilevskaya, Muthu Selvakumaran, Lucia Cabal Hierro, et al.
Oncogene|November 13, 2021
Mutant p53 elicits context-dependent pro-tumorigenic phenotypesJennifer J McCann, Irina A Vasilevskaya, Christopher McNair, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Biochemical Pharmacology|July 5, 2005
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell linesIrina A Vasilevskaya, Peter J O'Dwyer
Molecular Pharmacology|April 26, 2008
Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatinIrina A Vasilevskaya, Muthu Selvakumaran, Peter J O'Dwyer
Cancer Research|June 18, 2003
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interactionIrina A Vasilevskaya, Tatiana V Rakitina, Peter J O'Dwyer
Cancer Research|December 26, 2003
Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signalingTatiana V Rakitina, Irina A Vasilevskaya, Peter J O'Dwyer
Biochemical Pharmacology|March 9, 2007
Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell linesTatiana V Rakitina, Irina A Vasilevskaya, Peter J O'Dwyer
Molecular Pharmacology|January 15, 2004
Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell linesIrina A Vasilevskaya, Tatiana V Rakitina, Peter J O'Dwyer
Molecular Cancer Research : MCR|May 25, 2016
JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to ChemotherapyIrina A Vasilevskaya, Muthu Selvakumaran, David Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2013
Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapyMuthu Selvakumaran, Ravi K Amaravadi, Irina A Vasilevskaya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2015
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging AgentsIrina A Vasilevskaya, Muthu Selvakumaran, Lucia Cabal Hierro, et al.
Oncogene|November 13, 2021
Mutant p53 elicits context-dependent pro-tumorigenic phenotypesJennifer J McCann, Irina A Vasilevskaya, Christopher McNair, et al.
Pageof 2